Treatment outcomes for AML patients
need to be improved
“Despite using cytogenetic and molecular-risk stratification, the current overall outcome of AML patients remains relatively poor. By using Cellworks biosimulation, we can know an individual patient’s response to drugs before treatment, thereby identifying the most efficacious therapy for each patient more quickly and improving overall outcomes for AML patients.”
Dr. Guido Marcucci, MD
City of Hope
“Therapy selection for AML patients is often based on information considering only cytogenetics and/or molecular aberrations and ignoring other patient-specific omics information that could potentially enable selection of more effective treatments. Cellworks biosimulation is more comprehensive and takes into consideration the downstream pathway impact of genomic, proteomic, transcriptomic and epigenomic aberrations of a patient’s disease.”
Dr. Anthony Stein, MD
City of Hope
Every patient's tumor has a unique mutation profile
Standard care guidelines only consider one mutation at a time, resulting in low response rates across cancer types
Treatment guidelines do not consider mutational interactions that often cause drug resistance
Genome sequencing technology has improved significantly but today's analysis of the output is inadequate
Personalized Therapy Biosimulation
Considers a patient’s
multi-gene mutations
and interactions
Delivers phenotype
predictions and identifies
patient-specific optimal therapies
Goes beyond NGS to
provide predictions
based on multiomic
data
How does personalized therapy
biosimulation work?
The Cellworks Biosimulation Platform is powered by the groundbreaking Cellworks Computational Omics Biology Model (CBM), a network of 4,000+ human genes, 30,000+ molecular species and 100+ signaling pathways
Therapy biosimulation reports predict each AML patient’s
unique response to cancer treatments
SINGULA™
Identifies best FDA approved treatment options for a patient with AML, based on the specific cancer mutations in the patient's multi-omic data.
Download Sample ReportWhy biosimulate cancer
therapy responses?
Know response before treatment
Select personalized therapies
Avoid ineffective treatments
Improve patient outcomes
Personalized Therapy Biosimulation predictions are
proven to be highly accurate
AML and MDS
90%
Therapy Response
Prediction Accuracy
myCare-204 Principal Investigators
Dr. Guido Marcucci, MD
Chair and Professor, Department of Hematologic Malignancies Translational Science; Director, Gehr Family Center for Leukemia Research; Chief, Division of Leukemia Research, City of Hope
Read Full bio
Dr. Anthony Stein, MD
Hematologist/Oncologist, Co-director, Gehr Family Center for Leukemia Research; Clinical Professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
Read Full biomyCare-204 Clinical Trial Process
